RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$57.16
-0.47 (-0.82%)
▼
5d:
-1.8%
30d:
-9.43%
90d:
+0.42%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RPRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: RPRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.42
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$43.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $57.16, which is considered oversold relative to its 30-day fair value range of $57.87 to $61.81. The stock's valuation (Forward PE: 10.0) is in line with its historical norms (9.2). At these levels, the market is pricing in 2.8% annual earnings growth.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $56.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RPRX scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $65.12 (+13.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $56.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RPRX scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $65.12 (+13.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$57.87 -
$61.81
Company Quality Score
70/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
91.4%
Protect Your Profits
Holding RPRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (72/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($65.12)
- BULLISH: Expecting earnings turnaround to 2.8% growth with 16.5% revenue growth
- CAUTION: Bottoming setup, but lagging the sector by 25% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$57.87 -
$61.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$56.96
Resistance Level
$59.07
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.97
Wall Street Target
$65.13
(+13.9%)
Revenue Growth (YoY)
16.5%
Earnings Growth (YoY)
-46.3%
Profit Margin
32.0%
Valuation Premium vs History
+2.8% premium
PE vs Historical
10.0 vs 9.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$58.76
(+3%)
2-Year Target
$60.41
(+6%)
3-Year Target
$62.10
(+9%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$57.31
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 7.3%)
$144.58
(+153%)
Base:
(SPY PE: 10.0, Growth: 7.3%)
$70.65
(+24%)
Bear:
(PE: 8.5, Growth: 7.3%)
$60.05
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 31.32 | Current EPS (TTM): $1.84
Bull Case
$126.79
(+122%)
Analyst growth 100.0%, PE expands to 34.5
Base Case
$115.26
(+102%)
Market implied 100.0%, PE stable at 31.3
Bear Case
$39.19
(-31%)
Severe decline -20.0%, PE contracts to 26.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 8:00 PM ET
Data refreshes hourly during market hours. Next update: 9:00 PM
Data refreshes hourly during market hours. Next update: 9:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
